Overcoming TRP Challenges in GBM Therapy with an Albumin Binding Radiopharmaceutical
Time: 3:45 pm
day: Conference Day 1
Details:
- Strategies to overcome common challenges of short-lived, rapidly clearing Targeted Radiopharmaceuticals (TRP)
- Transforming targeted radiotherapy with an Evans blue (EB) conjugate. EB binds to albumin, abundant in the blood, resulting in a longer circulatory half-life. Better tissue absorption, retention, and nephroprotection enhance the treatment
- Studies with EB-modified integrin binding peptide significantly improves pharmacokinetics of targeted peptide radiotherapeutics. We demonstrated: (i) efficacy in GBM model, (iii) target engagement and sustained tumor absorption in GBM patients, and (iii) synergistic effect with immunotherapy
- Enhancing the performance of targeting peptides against integrins, SSTR2 and other receptors reported to impact GBM justifies further TRP research
